From the Chair
Advertisement
Ajay Singh pays tribute to the late nephrologist and researcher Nicolaos Madias, MD, of Tufts Medical Center.
The four-pillar approach to treating diabetic kidney disease (DKD) has been endorsed by high-quality trials, such as FLOW.
IgA nephropathy (IgAN) is on the cusp of a transformational change in its treatment.
APRIL has emerged as a critical factor in the pathogenesis of IgAN and is the focus of several clinical development programs.
The benefit-risk ratio and considerations about unmet need are worth considering.
SGLT2i therapy is contraindicated in patients with type 1 diabetes mellitus (T1DM) who have CKD.
The first part of the dialysis moonshot is to prevent the need for dialysis.
Measuring eGFR and UACR is a key component of guideline-directed medical therapy for patients with CKD from type 2 diabetes.
The most important patients who should receive treatment with SGLT2 inhibitors are those with CKD and type 2 diabetes.
Sodium-glucose transport protein 2 (SGLT2) inhibitors (SGLT2i), or gliflozins, block SGLT2 cotransporters in the ...
From the Chair
...
From the Chair
...
Managing blood pressure is probably the most important intervention that a nephrologist pursues in slowing kidney ...
Approximately 221 million people worldwide have been diagnosed with infection from SARS-CoV-2, the virus that causes ...
The approval by the US FDA on August 23, 2021, of difelikefalin (marketed as Korsuva™ by Cara Therapeutics) is a major ...
In a thought-provoking Viewpoint article in JAMA Surgery1, Arthur Matas, MD, makes the case for introducing a regulated ...
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.